Small-Molecule Inhibition of CBX4/7 Hypersensitises Homologous Recombination-Impaired Cancer to Radiation by Compromising CtIP-Mediated DNA End Resection.
Hugh C OsborneBenjamin M FosterHazim Al-HazmiStefan MeyerIgor LarrosaChristine K SchmidtPublished in: Cancers (2024)
The therapeutic targeting of DNA repair pathways is an emerging concept in cancer treatment. Compounds that target specific DNA repair processes, such as those mending DNA double-strand breaks (DSBs), are therefore of therapeutic interest. UNC3866 is a small molecule that targets CBX4, a chromobox protein, and a SUMO E3 ligase. As a key modulator of DNA end resection-a prerequisite for DSB repair by homologous recombination (HR)-CBX4 promotes the functions of the DNA resection factor CtIP. Here, we show that treatment with UNC3866 markedly sensitises HR-deficient, NHEJ-hyperactive cancer cells to ionising radiation (IR), while it is non-toxic in selected HR-proficient cells. Consistent with UNC3866 targeting CtIP functions, it inhibits end-resection-dependent DNA repair including HR, alternative end joining (alt-EJ), and single-strand annealing (SSA). These findings raise the possibility that the UNC3866-mediated inhibition of end resection processes we define highlights a distinct vulnerability for the selective killing of HR-ineffective cancers.
Keyphrases
- dna repair
- dna damage
- small molecule
- circulating tumor
- dna damage response
- cell free
- single molecule
- induced apoptosis
- climate change
- oxidative stress
- nucleic acid
- cell death
- squamous cell carcinoma
- cell cycle arrest
- endoplasmic reticulum stress
- circulating tumor cells
- young adults
- radiation induced
- amino acid
- lymph node metastasis
- pi k akt